35 studies found for:    s0806
Show Display Options
Rank Status Study
1 Active, not recruiting Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
Conditions: Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma
Interventions: Drug: vorinostat;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: vincristine sulfate;   Drug: prednisone;   Other: laboratory biomarker analysis
2 Completed A Study of 5-FUci Versus CPT-11 Plus CDDP Versus S-1 Alone in Advanced Gastric Cancer
Condition: Gastric Cancer
Interventions: Drug: continuous infusion of 5-fluorouracil;   Drug: combination of irinotecan and cisplatin;   Drug: oral administration of S-1
3 Unknown  S-1 or Tegafur-Uracil in Treating Patients With Previously Treated Stage III or Stage IV Head and Neck Cancer
Condition: Head and Neck Cancer
Interventions: Drug: tegafur-gimeracil-oteracil potassium;   Drug: tegafur-uracil;   Procedure: adjuvant therapy
4 Recruiting A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
Condition: Gastric Cancer
Interventions: Drug: taxane;   Drug: trastuzumab emtansine
5 Recruiting A Study of Kadcyla (Trastuzumab Emtansine) Plus Perjeta (Pertuzumab) Following Anthracyclines in Comparison With Herceptin (Trastuzumab) Plus Perjeta and a Taxane Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer
Condition: Breast Cancer
Interventions: Drug: anthracycline-based chemotherapy;   Drug: pertuzumab [Perjeta];   Drug: taxane;   Drug: trastuzumab [Herceptin];   Drug: trastuzumab emtansine [Kadcyla]
6 Recruiting A Randomized Phase 3 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) Compared to Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "OAK"
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: MPDL3280A;   Drug: docetaxel
7 Recruiting A Trial of Neoadjuvant TS-1 and Cisplatin for Type 4 and Large Type 3 Gastric Cancer
Condition: Gastric Neoplasm
Interventions: Procedure: Gastrectomy with more than D2 dissection;   Drug: Neoadjuvant chemotherapy(TS-1+CDDP) followed by gastrectomy
8 Unknown  Rituximab+Standard CHOP vs Rituximab+bi-Weekly CHOP for Untreated Stage III/IV Low-Grade B-Cell Lymphoma (JCOG0203)
Condition: Lymphoma, B-Cell
Interventions: Drug: Rituximab + Standard CHOP;   Drug: Rituximab + Bi-weekly CHOP
9 Recruiting A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) and Chemotherapy in Patients With HER2-Positive Metastatic Gastroesophageal Junction or Gastric Cancer
Condition: Gastric Cancer
Interventions: Drug: 5-fluorouracil;   Drug: capecitabine;   Drug: cisplatin;   Drug: pertuzumab [Perjeta];   Drug: placebo;   Drug: trastuzumab [Herceptin]
10 Completed A Study to Examine the Human Papillomavirus Types Exposure in Women From Southern Africa and Brasil
Conditions: HIV;   HIV Infections
Intervention:
11 Active, not recruiting
Has Results
Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Biological: trastuzumab;   Drug: docetaxel;   Drug: lapatinib ditosylate;   Drug: paclitaxel
12 Active, not recruiting Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Letrozole;   Drug: Anastrozole
13 Active, not recruiting A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Chemotherapy;   Drug: pertuzumab;   Drug: placebo;   Drug: trastuzumab [Herceptin]
14 Active, not recruiting Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Condition: Breast Cancer
Interventions: Drug: Placebo;   Drug: Denosumab
15 Completed
Has Results
Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.
Condition: Cardiovascular Diseases
Interventions: Drug: Telmisartan;   Drug: Combination of Telmisartan and Ramipril;   Drug: Ramipril
16 Active, not recruiting Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
Condition: Metastatic Renal Cell Carcinoma
Interventions: Drug: Dovitinib;   Drug: Sorafenib
17 Active, not recruiting A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE)
Condition: Breast Cancer
Interventions: Drug: docetaxel;   Drug: paclitaxel;   Drug: pertuzumab;   Drug: pertuzumab-placebo;   Drug: trastuzumab [Herceptin];   Drug: trastuzumab emtansine
18 Active, not recruiting Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Everolimus;   Drug: Placebo
19 Completed
Has Results
Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: tiotropium;   Drug: placebo
20 Unknown  Trial of TP Versus TC Regimens for Stage IVb, Persistent, or Recurrent Cervical Cancer (JCOG0505, CC-TPTC-P3)
Condition: Uterine Cervical Neoplasms
Interventions: Drug: chemotherapy: Paclitaxel/Cisplatin;   Drug: chemotherapy: Paclitaxel/Carboplatin

Previous Page Studies Shown (1-20) Next Page (21-35) Show next page of results
Indicates status has not been verified in more than two years